Hyaluronic Acid Injectable Gel VYC-25L Is Safe and Effective for Adults Seeking Chin Enhancement to Correct Chin Retrusion: Results From a Real-world Evidence Study in China

Abstract

Background

Chinese individuals may seek chin enhancement to address esthetic perceptions regarding chin retrusion. Because studies of the injectable hyaluronic acid gel VYC-25L (Allergan Aesthetics, an AbbVie Company, Irvine, CA) contained few Asian subjects and none from China, its effects on chin retrusion in Chinese individuals are unclear. This 12-month, real-world evidence study evaluated the safety and effectiveness of VYC-25L for chin enhancement in Chinese adults.

Methods

At Hainan Bo’ao Super Hospital, 2 cohorts of prospectively and retrospectively enrolled adults received VYC-25L treatment (maximum 4 mL). Cohort 1 only underwent 3D imaging before and after treatment for digital analysis. The primary effectiveness measure was mean change from baseline in glabella–subnasale–pogonion (G–Sn–Pog) angle at month 3 based on 3D facial images. Both cohorts completed the Global Aesthetic Improvement Scale (GAIS; subjects and investigators) and a satisfaction questionnaire (subjects). Injection site response (ISR) and adverse events were recorded.

Results

Of 90 subjects enrolled (cohort 1, n=36; cohort 2, n=54), 89 completed the study. Mean change from baseline in G–Sn–Pog angle at month 3 was 3.19 degrees (95% CI, 2.55–3.83; P < 0.001 vs 0), with improvement maintained through 12 months. Month 3 “improved”/“much improved” GAIS responder frequencies were 94.3% (investigators) and 97.1% (subjects); 91.5% of subjects were “satisfied”/“very satisfied” with treatment at month 3. Most (>70%) ISRs were mild or moderate in severity. Four treatment-related adverse events occurred (all mild).

Conclusion

VYC-25L was safe and effective for enhancement of the chin and jaw in Chinese adults.

Level of Evidence III

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.